When you are planning your pre-clinical development setup, it is important to know that the model system, you are applying, translates well into human use. This may be challenging to predict, even if you have previous data from similar, but not identical setups. However, if your preclinical model system does not translate well into human use, you may make conclusions that are based on an uncertain biological translational foundation and thus jeopardize significant investments in time and money during your pre-clinical work.
Intomics track record:
We have helped pharmaceutical companies with translations from animal models to humans for a range of disease areas. In some projects, we identified areas where translation from animal model to human were well preserved, but in others we demonstrated, that only parts of the implicated phenotypical traits from humans were present in the same regulatory structure in the chosen animal model system. In the latter situation, the model system may not sufficiently mimic the human application.
The value to our customers:
Performing this translational investigation ensures that you have the highest probability of success in the transition from the pre-clinical to clinical phase.
What we do:
For our preclinical model Translation Service, we perform an in-depth search of the reaction(s) or pathway(s), that your drug is aimed at, and elucidate how this is structured and regulated both in the model system(s) of interest and in humans. The search involve data mining and understanding of protein pathways and networks to investigate and identify novel drug targets. The text mining includes our proprietary inBio Know™ data mining platform and for protein-protein interaction networks we apply our proprietary PPI network database, inBio Map™, as well as client and publicly available databases.
We work closely with our clients in the planning of each project. Each project is tailored specifically to generate the most valuable outcome, taking available data, in-house capabilities, timelines etc. into account.
The duration of Translational Service projects is usually from 4 to 12 months, depending on the complexity of the project.
Close project cooperation and communication:
A key factor in the successful outcomes with our partners, is the close interaction and communication we have from planning the projects and all the way through project execution and presentation of the project deliverables. We typically have bi-weekly Webex update/planning meetings with the client and have face-to-face meetings every 2-3 months during the project. At the end of the project, we present the project deliverables and conclusions in a face-to-face meeting. All face-to-face meetings take place at our clients’ facility, unless another location is desired.
The deliverable is an overview of the reaction or pathway of interest, showing all relevant reactions and pathway structures in humans as well as the animal system(s) of interest. Additionally, the comprehensive report also details key project findings as well as important process steps and materials. Additionally, we present potential next steps in the project for discussion, if relevant.
What we do
Drug target identification
Helping clients identify genes/proteins as target candidates with remarkable results.
Helping clients uncover clinical relevant biomarkers in complex diseases enabling precise patient stratification.
Helping clients in investigating the potential of repositioning marketed drugs into other disease areas.
Helping clients decide on the correct model test platform for optimal drug development results.
Helping clients build and evolve their inhouse bioinformatic capabilities with expert counseling.